Jung-Yeon Yoo

Title: Jung-Yeon Yoo: Innovator in Monoclonal Antibodies

Introduction

Jung-Yeon Yoo is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies.

Latest Patents

Jung-Yeon Yoo holds a patent for SH3YL1 antibodies, compositions comprising the same, and vectors and uses thereof. The present disclosure relates to SH3YL1 monoclonal antibodies and compositions that include these antibodies. It also encompasses isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors containing these nucleic acid molecules, and host cells that incorporate the vectors. Furthermore, the patent outlines methods for modulating an immune response, treating diabetic nephropathy, and addressing non-alcoholic steatosis hepatitis through the administration of SH3YL1 antibodies. Additionally, it includes methods for treating acute kidney injury and inflammatory bowel disease using these antibodies.

Career Highlights

Throughout his career, Jung-Yeon Yoo has worked with notable companies in the biotechnology sector, including Celros Biotech and Aptabio Therapeutics Inc. His work has been instrumental in advancing therapeutic options in various medical fields.

Collaborations

Jung-Yeon Yoo has collaborated with several professionals in his field, including Yun Soo Bae and Eunjung An, who have contributed to his research and development efforts.

Conclusion

Jung-Yeon Yoo's innovative work in monoclonal antibodies and his contributions to biotechnology highlight his role as a key inventor in the industry. His patent on SH3YL1 antibodies represents a significant advancement in therapeutic applications.